Picture of AstraZeneca logo

AZN AstraZeneca News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

REG - AstraZeneca PLC - Director Declaration <Origin Href="QuoteRef">AZN.L</Origin>

RNS Number : 5577H
AstraZeneca PLC
18 August 2016

18 August 2016 13:00

New external board appointment

Listing Rule LR 9.6.14 R (2)

Graham Chipchase, a Non-Executive Director of AstraZeneca PLC, has been appointed as Chief Executive Officer and a Director of Brambles Limited, a company listed on the Australian Securities Exchange, effective from 2017.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

Media Enquiries

Neil Burrows

UK/Global

+44 203 749 5637

Vanessa Rhodes

UK/Global

+44 203 749 5736

Karen Birmingham

UK/Global

+44 203 749 5634

Rob Skelding

UK/Global

+44 203 749 5821

Jacob Lund

Sweden

+46 8553260 20

Michele Meixell

US

+1 302 885 2677

Investor Relations



UK



Thomas Kudsk Larsen

+44 203 749 5712

Craig Marks

Finance, Fixed Income, M&A

+44 7881 615 764

Nick Stone

Respiratory & Autoimmunity

+44 203 749 5716

Henry Wheeler

Oncology

+44 203 749 5797

Christer Gruvris

Infection & Neuroscience

+44 203 749 5711

US



Lindsey Trickett

Cardiovascular & Metabolic Diseases

+1 240 543 7970

Mitchell Chan

Oncology

+1 240 477 3771

Toll-free


+1 866 381 7277

Adrian Kemp

Company Secretary

AstraZeneca PLC

-ENDS-


This information is provided by RNS
The company news service from the London Stock Exchange
END
RDNBVLFFQVFFBBX

Recent news on AstraZeneca

See all news